Oxford BioMedica plc (OXB)

OXB, formerly known as Oxford BioMedica plc, is a global quality and innovation-led cell and gene therapy Contract Development and Manufacturing Organisation (CDMO) headquartered in Oxford, UK. The company's core mission is to enable its clients to deliver life-changing therapies to patients worldwide, leveraging its expertise in gene-based medicines.

OXB provides end-to-end CDMO solutions, supporting clients from pre-clinical development through to commercial launch. Its comprehensive services encompass various viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus, along with other viral vector types. The company also offers proprietary platforms such as LentiVector™ and inAAVate™.

In September 2024, Oxford BioMedica rebranded to OXB, a move that signifies its evolution into a pure-play cell and gene therapy CDMO with a global footprint. Frank Mathias serves as the Chief Executive Officer. The company operates state-of-the-art GMP facilities across the UK, US, and France, and in September 2023, it acquired ABL Europe. OXB has also been involved in significant collaborations, including a partnership with the Jenner Institute, Oxford University, in April 2020 for the development and manufacture of a COVID-19 vaccine.